$ATNM
Actinium Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000121390023082459 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $81.00K $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.306M $2.729M $3.958M
YoY Change -41.74% -11.19% 49.08%
% of Gross Profit
Research & Development $8.118M $11.62M $7.333M
YoY Change 10.71% 71.64% 35.4%
% of Gross Profit
Depreciation & Amortization $199.0K $200.0K $161.0K
YoY Change 23.6% -9.5% 17.52%
% of Gross Profit
Operating Expenses $10.42M $14.35M $11.29M
YoY Change -7.68% 45.78% 39.9%
Operating Profit -$14.35M
YoY Change 46.45%
Interest Expense $1.019M $1.075M $644.0K
YoY Change 58.23% 230.77% 1594.74%
% of Operating Profit
Other Income/Expense, Net $1.075M
YoY Change 230.77%
Pretax Income -$9.324M -$13.28M -$10.65M
YoY Change -12.43% 40.13% 32.92%
Income Tax
% Of Pretax Income
Net Earnings -$9.324M -$13.28M -$10.65M
YoY Change -12.43% 40.13% 32.92%
Net Earnings / Revenue -11511.11%
Basic Earnings Per Share -$0.49
Diluted Earnings Per Share -$0.34 -$0.49 -$0.42
COMMON SHARES
Basic Shares Outstanding 27.41M shares 27.00M shares 25.48M shares
Diluted Shares Outstanding 27.06M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.68M $82.98M $108.9M
YoY Change -29.6% -25.79% 39.93%
Cash & Equivalents $76.68M $82.98M $108.9M
Short-Term Investments
Other Short-Term Assets $1.586M $2.618M $2.032M
YoY Change -21.95% 62.81% 5.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $78.26M $85.60M $110.9M
YoY Change -29.46% -24.53% 39.11%
LONG-TERM ASSETS
Property, Plant & Equipment $2.869M $601.0K $604.0K
YoY Change 375.0% -5.35% 77.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $313.0K $310.0K $302.0K
YoY Change 3.64% 3.33%
Total Long-Term Assets $3.182M $3.348M $3.250M
YoY Change -2.09% -1.33% 408.61%
TOTAL ASSETS
Total Short-Term Assets $78.26M $85.60M $110.9M
Total Long-Term Assets $3.182M $3.348M $3.250M
Total Assets $81.45M $88.94M $114.2M
YoY Change -28.68% -23.86% 42.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.953M $8.150M $10.13M
YoY Change -21.49% 3.57% 83.02%
Accrued Expenses $530.0K $521.0K $494.0K
YoY Change 7.29% 34.97% 101.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $11.00K $1.000K $4.000K
YoY Change 175.0% -75.0% -93.55%
Total Short-Term Liabilities $8.494M $8.672M $10.63M
YoY Change -20.08% 3.86% 55.38%
LONG-TERM LIABILITIES
Long-Term Debt $19.00K $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $36.55M $36.69M $37.08M
YoY Change -1.43% -1.4%
Total Long-Term Liabilities $36.57M $36.69M $37.08M
YoY Change -1.38% -1.4% 1236000.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.494M $8.672M $10.63M
Total Long-Term Liabilities $36.57M $36.69M $37.08M
Total Liabilities $45.07M $45.36M $47.71M
YoY Change -5.54% -0.44% 597.22%
SHAREHOLDERS EQUITY
Retained Earnings -$337.6M -$328.3M -$288.8M
YoY Change 16.91% 18.03% 12.91%
Common Stock $28.00K $27.00K $26.00K
YoY Change 7.69% 8.0% 18.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.38M $43.58M $66.48M
YoY Change
Total Liabilities & Shareholders Equity $81.45M $88.94M $114.2M
YoY Change -28.68% -23.86% 42.05%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$9.324M -$13.28M -$10.65M
YoY Change -12.43% 40.13% 32.92%
Depreciation, Depletion And Amortization $199.0K $200.0K $161.0K
YoY Change 23.6% -9.5% 17.52%
Cash From Operating Activities -$7.490M -$11.13M -$7.778M
YoY Change -3.7% 94.66% 53.96%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $30.00K $16.00K
YoY Change -100.0% -141.1%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$30.00K -$16.00K
YoY Change -100.0% -58.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.192M 2.860M 4.893M
YoY Change -75.64% 81.59% 510.86%
NET CHANGE
Cash From Operating Activities -7.490M -11.13M -7.778M
Cash From Investing Activities 0.000 -30.00K -16.00K
Cash From Financing Activities 1.192M 2.860M 4.893M
Net Change In Cash -6.298M -8.295M -2.901M
YoY Change 117.1% 96.89% -31.76%
FREE CASH FLOW
Cash From Operating Activities -$7.490M -$11.13M -$7.778M
Capital Expenditures $0.00 $30.00K $16.00K
Free Cash Flow -$7.490M -$11.16M -$7.794M
YoY Change -3.9% 97.71% 54.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23691218 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25164599 shares
CY2023Q3 us-gaap Revenues
Revenues
usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26329298 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36374
dei Entity Registrant Name
EntityRegistrantName
ACTINIUM PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
74-2963609
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
677-3870
dei Entity Address Address Line1
EntityAddressAddressLine1
275 Madison Avenue, 7th Fl
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10016
dei Security12b Title
Security12bTitle
Common stock, par value $0.001
dei Trading Symbol
TradingSymbol
ATNM
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27413441 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82978000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
108910000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
396000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2618000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1636000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
85596000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
110942000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
643000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
487000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
601000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
604000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
302000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2436000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2341000 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1000 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
3000 usd
CY2023Q3 us-gaap Assets
Assets
88944000 usd
CY2022Q4 us-gaap Assets
Assets
114192000 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
8150000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
10130000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
521000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
494000 usd
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1000 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8672000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10628000 usd
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35000000 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35000000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1689000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2083000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
45361000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
47711000 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27413441 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27413441 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25674823 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25674823 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
27000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
26000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
371815000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
355220000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-328259000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-288765000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
43583000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
66481000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
88944000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
114192000 usd
CY2022Q3 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
45000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
1030000 usd
CY2022Q3 us-gaap Revenues
Revenues
45000 usd
us-gaap Revenues
Revenues
1030000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11622000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6771000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30552000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15802000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2729000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3073000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11025000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8041000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
14351000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9844000 usd
us-gaap Operating Expenses
OperatingExpenses
41577000 usd
us-gaap Operating Expenses
OperatingExpenses
23843000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14351000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9799000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-41577000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22813000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1075000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
325000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2083000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
443000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1075000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
325000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2083000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
443000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13276000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9474000 usd
us-gaap Net Income Loss
NetIncomeLoss
-39494000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22370000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27058397 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25164599 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26329298 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23691218 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
66481000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
993000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
770000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11037000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
57208000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1001000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9788000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
261000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15181000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
53077000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
921000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2861000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13276000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
43583000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
73545000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
421000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5129000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
68837000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
425000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16686000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7767000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
78181000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
970000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1578000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9474000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
71255000 usd
us-gaap Net Income Loss
NetIncomeLoss
-39494000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22370000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2915000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1816000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
591000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
538000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
982000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-264000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1981000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2334000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-907000 usd
atnm Increase Decrease In Longterm License Revenues Deferred
IncreaseDecreaseInLongtermLicenseRevenuesDeferred
35000000 usd
atnm Increase Decrease In Operating Lease Rightofuse Assets
IncreaseDecreaseInOperatingLeaseRightofuseAssets
-527000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-367000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-253000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39845000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16422000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
153000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
350000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-153000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-350000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
48000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13419000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18264000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
262000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13678000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18216000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-26320000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
34288000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109608000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78221000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83288000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112509000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>- The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
82978000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
108910000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
396000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
302000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83288000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109608000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5051000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4935000 shares
CY2012Q2 us-gaap Entertainment License Agreement For Program Material Capitalized Cost
EntertainmentLicenseAgreementForProgramMaterialCapitalizedCost
1000000 usd
CY2012Q2 us-gaap Derivative Net Assets Percentage
DerivativeNetAssetsPercentage
0.02 pure
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
5 years 2 months
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2027-07-30
us-gaap Payments For Rent
PaymentsForRent
600000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
173000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
206000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
518000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
440000 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1000 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
14000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
54000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
1000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
14000 usd
us-gaap Lease Cost
LeaseCost
3000 usd
us-gaap Lease Cost
LeaseCost
56000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
453000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
302000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
48000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2605000 usd
atnm Schedule Or Description Of Weighted Average Term
ScheduleOrDescriptionOfWeightedAverageTerm
Weighted average remaining lease terms are as follows at September 30, 2023:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining lease term:</td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%"> </td> <td style="text-align: center; width: 11%">  3.8 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance Leases</td><td> </td> <td style="text-align: center">  0.3 year</td></tr> </table>
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M18D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
44 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
214 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.21
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3304 shares
atnm Schedule Of Weighted Average Discount Rate
ScheduleOfWeightedAverageDiscountRate
weighted average discount rates used at the time that the leases were evaluated:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average discount rates: </span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating leases</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance Leases</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.0</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table>
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.048 pure
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.08 pure
CY2008Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
153000 usd
CY2008Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1000 usd
CY2008Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
618000 usd
CY2008Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
630000 usd
CY2008Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
643000 usd
CY2008Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
380000 usd
CY2008Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2424000 usd
CY2008Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1000 usd
CY2008Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
214000 usd
CY2008Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2210000 usd
CY2008Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
900000 usd
us-gaap Other Income
OtherIncome
100000 usd
CY2022Q2 us-gaap Advance Royalties
AdvanceRoyalties
35000000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3396 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15204000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
166 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.67
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M20D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1741000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1322 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.54
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M28D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
496000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Range Of Dividends Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRangeOfDividendsUsed
zero
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
325 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
5 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
25 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
7.31
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
305 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.89
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
CY2023Q3 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
atnm Increase Decrease In Longterm License Revenues Deferred
IncreaseDecreaseInLongtermLicenseRevenuesDeferred
usd
atnm Increase Decrease In Operating Lease Rightofuse Assets
IncreaseDecreaseInOperatingLeaseRightofuseAssets
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
usd
CY2008Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
usd
CY2008Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
usd
CY2008Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
usd
CY2008Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
usd
CY2008Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001388320

Files In Submission

Name View Source Status
0001213900-23-082459-index-headers.html Edgar Link pending
0001213900-23-082459-index.html Edgar Link pending
0001213900-23-082459.txt Edgar Link pending
0001213900-23-082459-xbrl.zip Edgar Link pending
atnm-20230930.xsd Edgar Link pending
f10q0923ex10-1_actiniumphar.htm Edgar Link pending
f10q0923ex31-1_actiniumphar.htm Edgar Link pending
f10q0923ex31-2_actiniumphar.htm Edgar Link pending
f10q0923ex32-1_actiniumphar.htm Edgar Link pending
f10q0923ex32-2_actiniumphar.htm Edgar Link pending
f10q0923_actiniumphar.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
image_005.jpg Edgar Link pending
image_006.jpg Edgar Link pending
image_007.jpg Edgar Link pending
image_008.jpg Edgar Link pending
image_009.jpg Edgar Link pending
image_010.jpg Edgar Link pending
image_011.jpg Edgar Link pending
image_012.jpg Edgar Link pending
image_013.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
atnm-20230930_def.xml Edgar Link unprocessable
atnm-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atnm-20230930_cal.xml Edgar Link unprocessable
atnm-20230930_pre.xml Edgar Link unprocessable
f10q0923_actiniumphar_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending